The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain.
The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain in
BOSTON — Treatment with LX9211 reduced pain related to postherpetic neuralgia and may be a valuable addition to current options for peripheral neuropathic pain, according to a presenter at the American Academy of Neurology annual meeting.“LX9211 is a nonopioid, oral medication designed to exert minimal effects by limiting activity of the [adapter protein-2 associated kinase 1
LX9211 demonstrated clear evidence of effect, achieving Lexicon’s goal for the study of supporting advancement in another indication within neuropathic.
Lexicon Pharma (LXRX) Reports Topline Results From Phase 2 Proof-of-Concept Study of LX9211 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.